Epigenome-wide methylation study identified two novel CpGs associated with T2DM risk and a network of co-methylated CpGs capable of patient’s classifications
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddad084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Anil K Giri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Molecular Medicine Unit, CSIR-Institute of Genomics and Integrative Biology, New Delhi 110025, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, MicroRNAs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Jawaharlal Nehru University, New Delhi, India, Council of Scientific and Industrial Research (CSIR), Government of India.
Abstract (Originalsprache)
Prevention of Type 2 diabetes mellitus (T2DM) pandemic needs markers that can precisely predict the disease risk in an individual. Alterations in DNA methylations due to exposure towards environmental risk factors are widely sought markers for T2DM risk prediction. To identify such individual DNA methylation signatures and their effect on disease risk, we performed an epigenome-wide association study (EWAS) in 844 Indian individuals of Indo-European origin. We identified and validated methylation alterations at two novel CpG sites in MIR1287 (cg01178710) and EDN2-SCMH1 (cg04673737) genes associated with T2DM risk at the epigenome-wide-significance-level (P < 1.2 × 10−7). Further, we also replicated the association of two known CpG sites in TXNIP, and CPT1A in the Indian population. With 535 EWAS significant CpGs (P < 1.2 × 10−7) identified in the discovery phase samples, we created a co-methylation network using weighted correlation network analysis and identified four modules among the CpGs. We observed that methylation of one of the module associates with T2DM risk factors (e.g. BMI, insulin and C-peptide) and can be used as markers to segregate T2DM patients with good glycemic control (e.g. low HbA1c) and dyslipidemia (low HDL and high TG) from the other patients. Additionally, an intronic SNP (rs6503650) in the JUP gene, a member of the same module, associated with methylation at all the 14 hub CpG sites of that module as methQTL. Our network-assisted EWAS is the first to systematically explore DNA methylation variations conferring risks to T2DM in Indians and use the identified risk CpG sites for patient segregation with different clinical outcomes. These findings can be useful for better stratification of patients to improve the clinical management and treatment effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genomics and Molecular Medicine Unit, CSIR-Institute of Genomics and Integrative Biology, New Delhi 110025, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
- Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi 110029, India.
- Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India.
ORCID-Profile: Dwaipayan Bharadwaj
Förderung
- Jawaharlal Nehru University, New Delhi, India
- Council of Scientific and Industrial Research (CSIR), Government of India
Zitieren
APA
Giri, A. K., Prasad, G., Parekatt, V., Rajashekar, D., Tandon, N., & Bharadwaj, D. (2023). Epigenome-wide methylation study identified two novel CpGs associated with T2DM risk and a network of co-methylated CpGs capable of patient’s classifications. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddad084
Vancouver
Giri AK, Prasad G, Parekatt V, Rajashekar D, Tandon N, Bharadwaj D. Epigenome-wide methylation study identified two novel CpGs associated with T2DM risk and a network of co-methylated CpGs capable of patient’s classifications. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddad084
BibTeX
@article{Giri2023,
author = {Giri, Anil K and Prasad, Gauri and Parekatt, Vaisak and Rajashekar, Donaka and Tandon, Nikhil and Bharadwaj, Dwaipayan},
title = {Epigenome-wide methylation study identified two novel CpGs associated with T2DM risk and a network of co-methylated CpGs capable of patient’s classifications},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddad084}
}
EUVIMED